1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2015

Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2015" provides an overview of Membranous Glomerulonephritis clinical trials scenario. This report provides top line data relating to the clinical trials on Membranous Glomerulonephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Membranous Glomerulonephritis Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials 15
Clinical Trials by Phase in E7 Countries 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Top Companies Participating in Membranous Glomerulonephritis Therapeutics Clinical Trials 24
Prominent Drugs 25
Clinical Trial Profile Snapshots 26
Appendix 37
Abbreviations 37
Definitions 37
Research Methodology 38
Secondary Research 38
About GlobalData 39
Contact Us 39
Disclaimer 39
Source 40

List of Tables
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Region, 2015* 6
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Membranous Glomerulonephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 9
Membranous Glomerulonephritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Membranous Glomerulonephritis Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 12
Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 15
Membranous Glomerulonephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 16
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Phase, 2015* 17
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 18
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 21
Membranous Glomerulonephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 22
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 23
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 24
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 25

List of Figures
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Membranous Glomerulonephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 9
Membranous Glomerulonephritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Membranous Glomerulonephritis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015* 12
Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Membranous Glomerulonephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Membranous Glomerulonephritis to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015* 15
Membranous Glomerulonephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 16
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 17
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 18
Membranous Glomerulonephritis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 21
Membranous Glomerulonephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 22
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 23
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 24
Membranous Glomerulonephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 25
GlobalData Methodology 38

Companies Mentioned
GlaxoSmithKline Plc
Novartis AG
Hanmi Science Co., Ltd.
F. Hoffmann-La Roche Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.